VolitionRx Secures EUR 2.0 Million Funding

VolitionRx Limited, a multinational epigenetics company, has secured an additional €2.0 million in non-dilutive funding from regional government agencies in Belgium. This significant financial injection will support the company's ongoing research and development efforts in its field. The non-dilutive nature of the funding is particularly beneficial, as it does not require VolitionRx to issue new shares, thus avoiding dilution for existing shareholders. This capital infusion is expected to accelerate the company's progress and strengthen its financial position.